Recent News

• 04.01.2025 - Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
• 04.01.2025 - Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
• 03.18.2025 - Korro Reports Full Year 2024 Financial Results and Provides Business Updates
• 03.18.2025 - Korro Reports Full Year 2024 Financial Results and Provides Business Updates
• 03.14.2025 - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
• 03.14.2025 - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
• 03.04.2025 - Korro Bio at the TD Cowen 45th Annual Health Care Conference
• 03.04.2025 - Korro Bio at the TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - Korro to Present at the TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - Korro to Present at the TD Cowen 45th Annual Health Care Conference

Recent Filings

• 03.27.2025 - 8-K Current report
• 03.18.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.18.2025 - 8-K Current report
• 03.18.2025 - EX-99.1 EX-99.1
• 03.18.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.11.2025 - 8-K Current report
• 02.11.2025 - 3 Initial statement of beneficial ownership of securities
• 02.05.2025 - 4 Statement of changes in beneficial ownership of securities